- United Kingdom
- /
- Semiconductors
- /
- AIM:KMK
Kromek Group Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Kromek Group (LON:KMK) Full Year 2024 Results
Key Financial Results
- Revenue: UK£19.4m (up 12% from FY 2023).
- Net loss: UK£3.29m (loss narrowed by 46% from FY 2023).
- UK£0.006 loss per share (improved from UK£0.014 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Kromek Group EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 7.6%. Earnings per share (EPS) exceeded analyst estimates by 25%.
The company's shares are down 22% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 5 warning signs for Kromek Group that you need to be mindful of.
Valuation is complex, but we're here to simplify it.
Discover if Kromek Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:KMK
Kromek Group
Develops, manufactures, and sells radiation detection components and devices for the medical imaging, civil nuclear, CBRNe security, and safety screening markets.
Moderate with mediocre balance sheet.